Please login to the form below

Not currently logged in
Email:
Password:

Dermira

This page shows the latest Dermira news and features for those working in and with pharma, biotech and healthcare.

Dermira craters as acne drug fails late-stage test

Dermira craters as acne drug fails late-stage test

Dermira’s acne candidate DRM01 failed to hit the mark in two phase III trials and this has left the company with a big hole in its pipeline that could take ... The fallout was particularly damaging for Dermira, which lost two-thirds of its share value

Latest news

  • Roche out-licenses lebrikizumab rights to Dermira Roche out-licenses lebrikizumab rights to Dermira

    Roche has opted to out-license the bulk of the rights to its IL-13 inhibitor lebrikizumab to dermatology company Dermira in a deal valued at up to $1.4bn. ... Now, the Swiss drug major has decided to let someone else take the lead on lebrikizumab, giving

  • UCB moves Cimzia into phase III trials for psoriasis UCB moves Cimzia into phase III trials for psoriasis

    Dr Iris Loew-Friendrich, chief medical officer and executive VP at UCB, commented: “Our collaboration with Dermira and the phase III psoriasis programme demonstrate our continued commitment to further investigate Cimzia ... Tom Wiggins, CEO of Dermira,

More from news
Approximately 3 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    Roche has licensed a monoclonal antibody in phase II to Dermira, a dermatology company. ... This is probably as much as Dermira can afford. It estimates that the development cost will be $200m to get the top line phase IIb study results and has cash

  • Deal Watch September 2016 Deal Watch September 2016

    Royalty range 4 -10%. 150. Dermira / Maruho. Licence. Exclusive licence to DRM04 topical anticholinergic for axillary hyperhidrosis; upfront $25m.

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    107. UCB/ Dermira. Licence ††. Cimzia (certolizumab pegol) - drug repurposing (p2 for psoriasis).

  • Pharma deals during July 2014 Pharma deals during July 2014

    dermatology specialist Dermira to develop Cimzia for psoriasis in the US, Canada and the EU. ... in Dermira and will invest up to a further $15m in its partner's future equity financings.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...

Infographics